Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 7, 2020Key data results:
Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2020 American Epilepsy Society (AES) Annual Meeting virtual conference....
-
Dec 1, 2020EMBARGOED UNTIL: 9:00 AM EST on December 4
Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 74th American Epilepsy Society (AES) Annual Meeting to be held from December...
Nov 20, 2020Results support 24 mg as the starting dose for LENVIMA in patients with radioactive iodine-refractory differentiated thyroid cancerEisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, at two starting doses:...
-
Nov 19, 2020Key findings reinforce safety and efficacy and dosing strategies of LENVIMA
Eisai announced today the presentation of three abstracts including investigational data in thyroid cancer and osteosarcoma at the European Society for Medical Oncology (ESMO) Asia Virtual...
Nov 10, 2020LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibKENILWORTH, N.J., and WOODCLIFF LAKE, N.J., November 10, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data...
- Nov 7, 2020Study 218 compares 18 mg and 14 mg starting doses of LENVIMA plus 5 mg everolimus in patients with clear-cell RCC following prior anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permitted
Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple...
- Nov 5, 2020Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE)
Eisai will present seven abstracts at the International Kidney Cancer Symposium (IKCS) 2020 from November 6-7, 2020. New investigational data from Study 218, a Phase 2 trial evaluating the safety...
-
Nov 2, 2020Nine presentations will highlight Eisai's investigational novel therapies being studied to treat Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including...
- Oct 27, 2020AMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19
LOS ANGELES – (BUSINESS WIRE)--Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA), and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) -- The Global Coalition for...
-
Sep 30, 2020Eisai Continues MOMENTUM 2 Expanded Access Program (Study 405) for Patients Previously Prescribed Lorcaserin to Treat Dravet and Other Refractory Epilepsies
Eisai Inc. announced today that, after consulting with the U.S. Food and Drug Administration (FDA), the Company has initiated a Phase 3 clinical study, MOMENTUM 1 (Study 304, NCT number pending),...